Aslanov Seymur, Gulsen Unal Nalan, Senkaya Ali, Celik Ferit, Murat Buyruk Abdullah, Uysal Alper, Akyildiz Murat, Turan Ilker, Gunsar Fulya, Ersoz Galip, Zeki Karasu Abdullah, Omer Ozutemiz Ahmet, Salih Akarca Ulus
Division of Gastroenterology, Department of Internal Medicine, University of Ege School of Medicine, Izmir, Turkey.
Division of Gastroenterology, Department of Internal Medicine, University of Koc School of Medicine, Istanbul, Turkey.
Hepatol Forum. 2021 Dec 5;3(1):3-10. doi: 10.14744/hf.2021.2021.0031. eCollection 2022 Jan.
Hepatocellular carcinoma (HCC) is one of the most common and most lethal cancers worldwide. The objective of this study was to investigate the relationship between basal parameters and survival characteristics in patients with HCC.
The records of 1447 HCC patients of a tertiary center during the period 2000-2017 were screened retrospectively. The demographic details; basal clinical, laboratory, and radiological characteristics; treatments; and survival time were recorded and prognostic scores were calculated.
A total of 788 patients with HCC (male/female: 623/165; mean age: 60.5±10.9 years) were included in the study. The median length of survival was 26.3 months (95% confidence interval [CI], 22.3-30.4 months). The 5-year survival rate was 28.1%. The number and diameter of the tumors; platelet count; platelet-to-lymphocyte ratio; level of aspartate aminotransferase, alanine aminotransferase, and gamma-glutamyl transferase; portal and hepatic vein involvement; and an alpha-fetoprotein level of <9.6 ng/mL were found to be independently related to survival.
The positive predictive value of the prognostic index derived from independent survival-related parameters for 5- and 10-year survival or overall survival was approximately 86%. Integration of this prognostic index to the criteria used in making treatment decisions for patients with HCC should be considered.
肝细胞癌(HCC)是全球最常见且致死率最高的癌症之一。本研究的目的是调查HCC患者的基础参数与生存特征之间的关系。
回顾性筛查了一家三级中心在2000年至2017年期间1447例HCC患者的记录。记录了人口统计学细节、基础临床、实验室和放射学特征、治疗情况及生存时间,并计算了预后评分。
本研究共纳入788例HCC患者(男/女:623/165;平均年龄:60.5±10.9岁)。中位生存时间为26.3个月(95%置信区间[CI],22.3 - 30.4个月)。5年生存率为28.1%。发现肿瘤数量和直径、血小板计数、血小板与淋巴细胞比值、天冬氨酸转氨酶、丙氨酸转氨酶和γ-谷氨酰转移酶水平、门静脉和肝静脉受累情况以及甲胎蛋白水平<9.6 ng/mL与生存独立相关。
由独立生存相关参数得出的预后指数对5年和10年生存或总生存的阳性预测值约为86%。应考虑将该预后指数纳入HCC患者治疗决策所用的标准中。